Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 Study of SMP-100 in Healthy Volunteers
NCT04296799Phase 1Completed
- Sponsor
- SciMount Pharmatech, Co. Ltd.
- Start
- Jun 2020
- Primary completion
- Jul 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of SMP-100 in irritable bowel syndrome (IBS), sponsored by SciMount Pharmatech, Co. Ltd. Primary endpoints: Safety and Tolerability Assessment (SAD) and Safety and Tolerability Assessment (MAD). Started Jun 2020; status: completed.
02
Drugs
SMP-100
03
Conditions
irritable bowel syndrome (IBS)
Beyond the preview
Go deeper on NCT04296799.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04296799.